5-minute walkthroughNo login requiredFor investors, hospital CMIOs, biotech BD leads

PetriDish in 5 minutes

Three real Indian clinical wedges PetriDish catches before the standard workflow. Click any card to see the evidence, the metrics, and the live module behind it. Total reading time: ~5 minutes. Live system is one click below each card.

90,650 nodes · 4.4M relationships

55 CPIC-graded PGx variants

100 IMPPAT phytochemicals · 50 curated epifactors

The India wedge

18% of South Asian children carry NUDT15 c.415C>T — 1.8× global rate. 6-mercaptopurine standard dose causes severe myelosuppression. CPIC says 30–50 mg/m²/day in heterozygotes, avoid in homozygotes.

18%

South Asian carrier rate

10%

Global carrier rate

CPIC level

50%

Dose reduction (het)

Maintenance phase of B-ALL. ANC drops to 200. Standard workflow: hold drug, give G-CSF, hope. PetriDish workflow: NUDT15 genotype already flagged at induction; dose reduced 50% from week 1; the crisis never happens. CPIC 1A — strongest possible evidence grade.

Evidence trail

PMID 33713620

NUDT15 c.415C>T frequency in Indian B-ALL cohort (TMC Mumbai)

CPIC 2018

Thiopurine guideline: TPMT + NUDT15 dose adjustment matrix

IndiGen 1029

CSIR-IGIB whole-genome panel — pan-India allele frequencies

Want to go deeper?

See live data state, knowledge-graph composition, and the validation roadmap.

Truth-in-claims: PetriDish is decision-support software, not a regulatory-approved diagnostic. Clinical recommendations cite their evidence grade and PMIDs. Indian frequencies blend IndiGen 1029-genome, GenomeAsia 100K, and published Indian cohort PMIDs — exact provenance is on /methods. No clinical validation paper yet — that's the next milestone.